Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

Mamidi RNVS, Dallas S, Sensenhauser C, Lim HK, Scheers E, Verboven P, Cuyckens F, Leclercq L, Evans DC, Kelley MF, Johnson MD, Snoeys J.

Br J Clin Pharmacol. 2017 May;83(5):1082-1096. doi: 10.1111/bcp.13186. Epub 2016 Dec 20.

PMID:
27862160
2.

Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.

Mamidi RN, Proctor J, De Jonghe S, Feyen B, Moesen E, Vinken P, Ma JY, Bryant S, Snook S, Louden C, Lammens G, Ways K, Kelley MF, Johnson MD.

Chem Biol Interact. 2014 Sep 25;221:109-18. doi: 10.1016/j.cbi.2014.08.001. Epub 2014 Aug 14.

PMID:
25130857
3.

Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate.

Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, Di Prospero NA, Pandina G, Singh JB, Ford L, Moyer JA, Nork TM, Ver Hoeve JN, Aguirre GD.

Regul Toxicol Pharmacol. 2014 Jul;69(2):187-200. doi: 10.1016/j.yrtph.2014.03.005. Epub 2014 Mar 26.

PMID:
24680767
4.

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, Lim HK.

Drug Metab Dispos. 2014 May;42(5):903-16. doi: 10.1124/dmd.113.056440. Epub 2014 Feb 25.

5.

Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants.

Leone A, Nie A, Brandon Parker J, Sawant S, Piechta LA, Kelley MF, Mark Kao L, Jim Proctor S, Verheyen G, Johnson MD, Lord PG, McMillian MK.

Toxicol Appl Pharmacol. 2014 Mar 15;275(3):189-97. doi: 10.1016/j.taap.2014.01.017. Epub 2014 Jan 29.

PMID:
24486436
6.

Teaching empathy and other compassion-based communication skills.

Kelley KJ, Kelley MF.

J Nurses Prof Dev. 2013 Nov-Dec;29(6):321-4. doi: 10.1097/01.NND.0000436794.24434.90.

PMID:
24256934
7.

Leading medical causes of mortality among male prisoners in Texas, 1992--2003.

Harzke AJ, Baillargeon JG, Kelley MF, Pruitt SL, Pulvino JS, Paar DP.

J Correct Health Care. 2011 Jul;17(3):241-53. doi: 10.1177/1078345811401362. Epub 2011 May 15.

PMID:
21576121
8.

Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies.

Eichenbaum G, Damsch S, Looszova A, Vandenberghe J, Van den Bulck K, Roels K, Megens A, Knight E, Hillsamer V, Feyen B, Kelley MF, Tonelli A, Lammens L.

J Appl Toxicol. 2011 May;31(4):342-54. doi: 10.1002/jat.1592. Epub 2010 Nov 18.

PMID:
21089156
9.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.

PMID:
20661737
10.

Prevalence of chronic medical conditions among inmates in the Texas prison system.

Harzke AJ, Baillargeon JG, Pruitt SL, Pulvino JS, Paar DP, Kelley MF.

J Urban Health. 2010 May;87(3):486-503. doi: 10.1007/s11524-010-9448-2.

11.

HCV-related mortality among male prison inmates in Texas, 1994-2003.

Harzke AJ, Baillargeon JG, Kelley MF, Diamond PM, Goodman KJ, Paar DP.

Ann Epidemiol. 2009 Aug;19(8):582-9. doi: 10.1016/j.annepidem.2009.03.009. Epub 2009 May 13.

12.

Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression.

Leone AM, Kao LM, McMillian MK, Nie AY, Parker JB, Kelley MF, Usuki E, Parkinson A, Lord PG, Johnson MD.

Chem Res Toxicol. 2007 Apr;20(4):600-8. Epub 2007 Mar 24.

PMID:
17381134
13.

Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.

Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):566-75. Epub 2007 Jan 12.

14.

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF.

Antimicrob Agents Chemother. 2006 Nov;50(11):3535-42.

15.

The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.

Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):554-65. Epub 2006 Aug 25.

16.

Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey.

Hemeryck A, Mamidi RN, Bottacini M, Macpherson D, Kao M, Kelley MF.

Xenobiotica. 2006 Jul;36(7):597-613.

PMID:
16864506
17.

Methicillin-resistant Staphylococcus aureus infection in the Texas prison system.

Baillargeon J, Kelley MF, Leach CT, Baillargeon G, Pollock BH.

Clin Infect Dis. 2004 May 1;38(9):e92-5. Epub 2004 Apr 14.

PMID:
15127360
18.
19.

Evaluating rabies exposure.

Kelley MF, Mahlow JC.

Tex Med. 2001 Apr;97(4):60-3. No abstract available.

PMID:
11344926
20.

Outbreak of histoplasmosis among cavers attending the National Speleological Society Annual Convention, Texas, 1994.

Ashford DA, Hajjeh RA, Kelley MF, Kaufman L, Hutwagner L, McNeil MM.

Am J Trop Med Hyg. 1999 Jun;60(6):899-903.

PMID:
10403317
21.

Social interaction among people with dementia.

Kelley MF.

J Gerontol Nurs. 1997 Apr;23(4):16-20. Review. No abstract available.

PMID:
9146180
22.

Subchronic toxicity studies with the leukotriene D4 antagonist RG 12525.

Bonnefoi MS, Kelley MF, Wells RE, Sanders JE, Jayyosi Z, Beys E, Kornbrust DJ, Langloss JM.

Fundam Appl Toxicol. 1995 Nov;28(1):129-38.

PMID:
8566477
23.

Older women and heart disease: beliefs about preventive behaviors.

Conn VS, Libbus MK, Thompson SE, Kelley MF.

Womens Health Issues. 1994 Fall;4(3):162-9. No abstract available.

PMID:
7950397
24.

TB transmission in hospitals.

Kelley MF.

Healthtexas. 1992 Jan-Feb;48(1):18-9. No abstract available.

PMID:
10116106
25.

Controlling tuberculosis in minority populations in Texas.

Wallace CE, Kelley MF, Bybee JA.

Tex Med. 1991 Oct;87(10):30-1. No abstract available.

PMID:
1962293
26.

Hib vaccine is available and soon to be required.

Kelley MF.

Tex Med. 1991 Jan;87(1):8. No abstract available.

PMID:
1998163
27.

Transforming growth factor beta 1 regulates production of acute-phase proteins.

Mackiewicz A, Ganapathi MK, Schultz D, Brabenec A, Weinstein J, Kelley MF, Kushner I.

Proc Natl Acad Sci U S A. 1990 Feb;87(4):1491-5.

28.

The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta.

Boehm KD, Kelley MF, Ilan J, Ilan J.

Proc Natl Acad Sci U S A. 1989 Jan;86(2):656-60.

29.

Kinetics of cell death and disintegration in human lymphocyte cultures.

Bernheim JL, Mendelsohn J, Kelley MF, Dorian R.

Proc Natl Acad Sci U S A. 1977 Jun;74(6):2536-40.

30.

Garre's disease in an Enga adolescent.

Kelley MF.

P N G Med J. 1975 Jun;18(2):122-3. No abstract available.

PMID:
1061457
31.
32.

AN ANALYSIS OF SUICIDE CALLS RECEIVED BY A PERSONAL EMERGENCY ADVISORY (TELEPHONE) SERVICE.

BARTHOLOMEW AA, KELLEY MF.

Med J Aust. 1963 Sep 21;17:488-92. No abstract available.

PMID:
14056572
33.

The personal emergency advisory service.

BARTHOLOMEW AA, KELLEY MF.

Ment Hyg. 1962 Jul;46:382-92. No abstract available.

PMID:
13865431

Supplemental Content

Loading ...
Support Center